From the Research
Sotatercept does not have a known association with elevation of serum globulins. Sotatercept is a novel activin receptor type IIA-Fc fusion protein that acts as a ligand trap for members of the TGF-beta superfamily, primarily used for treating pulmonary arterial hypertension (PAH) 1. Based on available clinical data, sotatercept's common side effects include headache, dizziness, fatigue, thrombocytopenia, and increased hemoglobin levels, but significant alterations in serum globulin levels have not been reported as a characteristic effect 2, 1. If a patient on sotatercept develops elevated serum globulins, other causes should be investigated, including inflammatory conditions, infections, liver disease, or monoclonal gammopathies. Regular monitoring of complete blood count is recommended during sotatercept therapy, but specific monitoring of globulin levels is not routinely indicated unless clinically warranted. The mechanism of action of sotatercept primarily affects erythropoiesis and vascular remodeling pathways rather than immunoglobulin production, which explains the lack of direct impact on serum globulin levels 3, 4. Some key points to consider when evaluating sotatercept's effects include:
- Sotatercept's efficacy in improving exercise capacity and delaying clinical worsening in patients with PAH 2, 1
- The potential for sotatercept to cause adverse events such as epistaxis, telangiectasia, and increased hemoglobin levels 2, 1
- The importance of monitoring patients on sotatercept for signs of thrombocytopenia and other hematologic adverse events 3, 5
- The need for further studies to evaluate the long-term effects of sotatercept on mortality and other outcomes in patients with PAH 2, 1